Food and Drug Administration (FDA) Postmarket Reported Side Effects and Adverse Events Associated with Pulmonary Hypertension Therapy in Pediatric Patients
- 876 Downloads
Because most medications for pediatric pulmonary hypertension (PH) are used off label and based on adult trials, little information is available on pediatric-specific adverse events (AEs). Although drug manufacturers are required to submit postmarket AE reports to the Food and Drug Administration (FDA), this information is rarely transmitted to practitioners. In the setting of a recent FDA warning for sildenafil, the authors sought to give a better description of the AEs associated with current therapies in pediatric PH. In January 2010, a written request was made to the Food and Drug Administration for AE records of commonly used PH medications. Reports were screened for pediatric patients, analyzed in terms of AEs, and compared with the medical literature. Arbitrarily, AEs that could be attributed to concomitant medications were not attributed to the PH medication in question. Adverse events occurring in more than 5 % of events for each drug were assumed to be associated with the targeted PH medication. Between November 1997 and December 2009, 588 pediatric AE reports (death in 257 cases) were reported for the three most commonly used therapies: bosentan, epoprostenol, and sildenafil. Many of the AEs were similar to those reported previously. However, 27 AEs not previously reported in the literature (e.g., pulmonary hemorrhage, hemoptysis, and pneumonia) were found. The FDA postmarket records for PH medications in pediatric patients show a significant number of AEs. The discovery of AEs not previously reported will better inform those caring for these complex and critically ill children, and the large number of deaths suggest they may be underreported in current literature.
KeywordsAdverse drug events Pediatrics Pulmonary hypertension
We thank Raymond R. Balise, PhD, for his assistance in the statistical analysis.
The University of Colorado receives fees for Dr. Ivy to be a consultant for Actelion, Gilead, Pfizer and United Therapeutics.
- 2.Adverse Event Reporting System (AERS) (2006) Background report definitions, and caveats. Department of Health and Human ServicesGoogle Scholar
- 4.Barst RJ, Layton G, Konourina I, Richardson H, Beghetti M, Ivy DD (2012) STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive patients with pediatric pulmonary arterial hypertension. Eur Heart J 33(Suppl 1):979Google Scholar
- 6.Cassens BJ (2010) Warning letters. Actelion Pharmaceuticals U.S., Inc. http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm227632.htm. Accessed 1 Jun 2011
- 7.FDA (2012) FDA drug safety communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension. http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm. Accessed 10 Jan 2013
- 8.Gilead Sciences (2007) I. U.S. Food and Drug Administration approves Gilead’s Letairis™ (ambrisentan) 5 mg and 10 mg tablets for the once-daily treatment of pulmonary arterial hypertension (WHO group 1) in patients with WHO functional class II or III symptoms. http://www.gilead.com/wt/sec/pr_1016053. Accessed 1 Jun 2011
- 10.United Therapeutics (2009) FDA approves adcirca (Tadalafil) tablets for the treatment of pulmonary arterial hypertension. http://ir.unither.com/releasedetail.cfm?. Accessed 1 Jun 2011